Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 299

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Sertraline versus other antidepressive agents for depression

Open access
Cipriani, Andrea, La Ferla, Teresa, Furukawa, Toshi A, Signoretti, Alessandra, Nakagawa, Atsuo, Churchill, Rachel, McGuire, Hugh, Barbui, Corrado·2010·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd006117.pub4
Open this paper in CoChat — free account

Abstract

BACKGROUND: Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice. OBJECTIVES: The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults. SEARCH METHODS: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis review group's specialised register (CCDANCTR), which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years to April 2011), EMBASE, (1980 to July 2011) MEDLINE (1950 to July 2011) and PsycINFO (1974 to July 2011). Reference lists of the reports of relevant studies were checked and experts in the field contacted. The review was not limited to English-language articles. SELECTION CRITERIA: Randomised controlled trials (RCTs) allocating participants with major depression to mirtazapine versus any other antidepressive agent. DATA COLLECTION AND ANALYSIS: Two authors independently checked eligibility and extracted data on an intention-to-treat basis. The primary outcome was response to treatment. The secondary outcomes included dropouts and individual adverse events.Meta-analyses were conducted using the random-effects model. MAIN RESULTS: A total of 29 RCTs (n = 4974), mostly following up the participants for six weeks in outpatient clinics and inadequately reporting the risk of bias, were included. In comparison with tricyclic antidepressants (10 trials, n = 1553) there was no robust evidence to detect a difference between mirtazapine and tricyclics in terms of response at two weeks (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.64 to 1.13) or at the end of acute-phase treatment (at 6 to 12 weeks) (OR 0.89, 95% CI 0.72 to 1.10). In comparison with selective serotonin reuptake inhibitors (SSRIs) (12 trials, n = 2626) mirtazapine was significantly more effective at two weeks (OR 1.57, 95% CI 1.30 to 1.88) and at the end of acute-phase treatment (OR 1.19, 95% CI 1.01 to 1.39). Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor (venlafaxine only, two trials, n = 415) at two weeks (OR 2.29, 95% CI 1.45 to 3.59) and at the end of acute-phase treatment (OR 1.53, 95% CI 1.03 to 2.25).In terms of dropouts, there was no robust evidence to detect a difference between mirtazapine and other antidepressants. Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction. AUTHORS' CONCLUSIONS: Some statistically significant and possibly clinically meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression. Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment. Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants, although the adverse event profile of mirtazapine is unique.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006117.pub4

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 115

  1. Aberg-Wistedt, 2000, Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy, Journal of Clinical Psychopharmacology, 20, 645, 10.1097/00004714-200012000-00010 · DOI
  2. Khoury A Aberg Wistedt A Stain Malmgren R Effect of sertraline and paroxetine treatment on depression scores and peripheral indices of serotonergic function in major depression 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October 4th November 1998 Utrecht ECNP 1998 · doi:10.1016/s0924-977x(98)80273-3
  3. Aguglia, 1993, Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression, International Clinical Psychopharmacology, 8, 197, 10.1097/00004850-199300830-00010 · DOI · Paper page
  4. Baca, 2003, Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27, 493, 10.1016/S0278-5846(03)00038-1 · DOI
  5. Behan, 1995, 5-HT reuptake inhibitors in CFS, EOS Rivista di Immunologia ed Immunofarmacologia, 15, 66
  6. Behnke, 2003, Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study, Journal of Clinical Psychopharmacology, 23, 358, 10.1097/01.jcp.0000085408.08426.05 · DOI
  7. Bennie, 1995, A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression, Journal of Clinical Psychiatry, 56, 229
  8. Bersani, 1994, A double-blind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes, Human Psychopharmacology, 9, 63, 10.1002/hup.470090108 · DOI
  9. Bondareff, 2000, Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life, American Journal of Psychiatry, 157, 729, 10.1176/appi.ajp.157.5.729 · DOI · Paper page
  10. Boyer, 1998, Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression A 6-month double-blind study in a primary-care setting in France, Pharmacoeconomics, 13, 157, 10.2165/00019053-199813010-00015 · DOI
  11. Brenner, 2000, Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study, Clinical Therapeutics, 22, 411, 10.1016/S0149-2918(00)89010-4 · DOI · Paper page
  12. Chen, 2001, Venlafaxine vs imipramine, sertraline in treating depression, Chinese Journal of New Drugs and Clinical Remedies, 20, 109
  13. Cohn, 1990, Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients, Journal of Clinical Psychiatry, 51, 28
  14. Coleman, 1999, Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment, Annals of Clinical Psychiatry, 11, 205, 10.3109/10401239909147072 · DOI
  15. Croft, 1999, A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline, Clinical Therapeutics, 21, 643, 10.1016/S0149-2918(00)88317-4 · DOI · Paper page
  16. Davidson, 2002, Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: A randomized controlled trial, JAMA, 287, 1807, 10.1001/jama.287.14.1807 · DOI · Paper page
  17. Doogan, 1994, A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice, International Clinical Psychopharmacology, 9, 95, 10.1097/00004850-199400920-00005 · DOI
  18. Eker, 2005, Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder, Turk Psikiyatri Dergisi, 16, 153
  19. Ekselius, 1997, A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general-practice, International Clinical Psychopharmacology, 12, 323, 10.1097/00004850-199711000-00005 · DOI
  20. Fava, 2000, Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression, Journal of Affective Disorders, 59, 119, 10.1016/S0165-0327(99)00131-7 · DOI
  21. Fava, 2002, Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia, Journal of Clinical Psychopharmacolog, 22, 137, 10.1097/00004714-200204000-00006 · DOI
  22. Feiger, 1996, Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction, Journal of Clinical Psychiatry, 57, 53
  23. Forlenza, 2001, Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: Results from a double-blind, randomized, controlled clinical trial, International Psychogeriatrics, 13, 75, 10.1017/S1041610201007475 · DOI
  24. Fournier, 1997, A double-blind comparison of sertraline and imipramine in outpatients with major depression: Acute (8 weeks) and continuation (16 weeks) treatment, Human Psychopharmacology, 12, 203, 10.1002/(SICI)1099-1077(199705/06)12:3<203::AID-HUP849>3.0.CO;2-V · doi:10.1002/(sici)1099-1077(199705/06)12:3<203::aid-hup849>3.0.co;2-v
  25. Gastpar, 2005, Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline, Pharmacopsychiatry, 38, 78, 10.1055/s-2005-837807 · DOI
  26. Hegerl, 1997, Sertraline versus amitriptyline in hospitalized patients with major depression, Pharmacopsychiatry, 30, 175
  27. Kamijima, 1997, A double-blind, group comparison study of sertraline by hydrochloride vs amitriptyline hydrochloride, Japanese Journal of Neuropsychopharmacology, 19, 529
  28. Kavoussi, 1997, Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients, Journal of Clinical Psychiatry, 58, 532, 10.4088/JCP.v58n1204 · DOI
  29. Lee, 1994, Efficacy of sertraline in dysthymia, Neuropsychopharmacology, 10, 222S
  30. Lepine, 2000, A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression, International Clinical Psychopharmacology, 15, 263, 10.1097/00004850-200015050-00003 · DOI · Paper page
  31. Li, 2001, A comparative study of sertraline and maprotiline in the treatment of depression, Shandong Journal of Psychological Medicine, 14, 173
  32. Lydiard, 1997, A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression, Journal of Clinical Psychiatry, 58, 484, 10.4088/JCP.v58n1104 · DOI
  33. Mehtonen, 2000, Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder, Journal of Clinical Psychiatry, 61, 95, 10.4088/JCP.v61n0204 · DOI
  34. Moller, 2000, Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression, Pharmacopsychiatry, 33, 206, 10.1055/s-2000-8357 · DOI
  35. Moon, 1994, A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general-practice, Journal of Psychopharmacology, 8, 171, 10.1177/026988119400800306 · DOI
  36. Munizza, 2006, A Comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder, Current medical research and opinion, 22, 1703, 10.1185/030079906X121039 · DOI
  37. Murasaki, 1997, Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor for depression and depressive state-A double-blind study compared with imipramine hydrochloride, Japanese Journal of Meuropsychopharmacology, 19, 505
  38. Nemeroff, 1995, Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients, Depression, 3, 163, 10.1002/depr.3050030402 · DOI
  39. Orsel Donbak, 1995, Moclobemide and sertraline in the treatment of depressive disorders: a comparative study, Acta Psychiatrica Belgica, 95, 139
  40. Oslin, 2003, Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents, Journal of Clinical Psychiatry, 64, 875, 10.4088/JCP.v64n0804 · DOI
  41. Quednow, 2004, Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression, Psychopharmacology, 175, 399
  42. Ravindran, 1995, The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression., Human Psychopharmacology, 10, 273, 10.1002/hup.470100404 · DOI
  43. Reimherr, 1990, Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression, Journal of Clinical Psychiatry, 51, 18
  44. Rossini, 2005, Sertraline versus Fluvoxamine in the treatment of elderly patients with major depression a double-blind, randomized trial., Journal of Clinical Psychopharmacology, 25, 471, 10.1097/01.jcp.0000177548.28961.e7 · DOI
  45. Sechter, 1999, A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients, European Psychiatry: the Journal of the Association of European Psychiatrists, 14, 41, 10.1016/S0924-9338(99)80714-7 · DOI
  46. Shelton, 2006, A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder, Journal of Clinical Psychiatry, 67, 1674, 10.4088/JCP.v67n1102 · DOI
  47. Sogaard, 1999, A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression, Journal of Psychopharmacology, 13, 406, 10.1177/026988119901300412 · DOI
  48. Stahl, 2000, Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline, Biological Psychiatry, 48, 894, 10.1016/S0006-3223(00)00957-4 · DOI
  49. Suri, 2000, Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder, Journal of Clinical Psychiatry, 61, 942, 10.4088/JCP.v61n1209 · DOI
  50. Szadoczky, 2002, Efficacy and acceptability of tianeptine and sertraline in the acute treatment phase of depression, Encephale, 28, 343
  51. Tsutsui, 1997, Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of depression and depressive state: a double-blind, group comparison study of sertraline hydrochloride vs trazodone hydrochloride, Shinkeiseishinyakuri, 19, 549
  52. Gurp, 2002, St John's wort or sertraline? Randomized controlled trial in primary care, Canadian Family Physician, 48, 905
  53. Moffaert, 1995, A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression, Human Psychopharmacology, 10, 393, 10.1002/hup.470100505 · DOI
  54. Ventura, 2007, Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial, Current Medical Research and Opinion, 23, 245, 10.1185/030079906X167273 · DOI
  55. Zanardi, 1996, Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression, American Journal of Psychiatry, 153, 1631, 10.1176/ajp.153.12.1631 · DOI
  56. Fava, 1997, A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia, Psychopharmacology Bulletin, 33, 101
  57. Finkel S Richter E Double-blind comparison of sertraline and nortriptyline in late-life depression 8th ECNP (European College of Neuropsychopharmacology) Congress. Venice, Italy Utrecht ECNP 1995 · doi:10.1016/0924-977x(95)90482-s
  58. Gonul, 1999, Selective serotonin reuptake inhibitors: discontinuation rates due to side effects, European Neuropsychopharmacology, 9, 215, 10.1016/S0924-977X(99)80132-1 · doi:10.1016/s0924-977x(99)80132-1
  59. Latimer PR Ravindran AV Bernatchez JP Fournier JP Gojer JA Barratt K & Buttars J A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression XXth Collegium Internationale Neuro psychopharmacologicum Melbourne, Australia 1996 · doi:10.1016/0924-977x(96)87876-x
  60. Malt, 1999, The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study, British Medical Journal, 318, 1180, 10.1136/bmj.318.7192.1180 · DOI
  61. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
  62. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
  63. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
  64. Barbui, 2000, Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD002791.pub2 · DOI
  65. Barbui, 2004, Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis, Pharmacopsychiatry, 37, 93, 10.1055/s-2004-818985 · DOI
  66. Bauer, 2002, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder, World J Biol Psychiatry, 3, 5, 10.3109/15622970209150599 · DOI · Paper page
  67. Bhandari, 2004, Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials, CMAJ, 170, 477
  68. Buchkowsky, 2004, Industry sponsorship and authorship of clinical trials over 20 years, Annals of Pharmacotherapy, 38, 579, 10.1345/aph.1D267 · DOI
  69. Cipriani, 2005, Fluoxetine versus other types of pharmacotherapy for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004185.pub2 · DOI
  70. Cipriani, 2007, Venlafaxine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews
  71. Cipriani, 2007, Paroxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews
  72. Cipriani, 2007, Venlafaxine for major depression, BMJ, 334, 215, 10.1136/bmj.39098.457720.BE · DOI
  73. Ciuna, 2004, Are we going to increase the use of antidepressants up to that of benzodiazepines?, European Journal of Clinical Pharmacology, 60, 629, 10.1007/s00228-004-0810-8 · DOI
  74. Davies, 2004, Treatment of anxiety and depressive disorders in patients with cardiovascular disease, BMJ, 328, 939, 10.1136/bmj.328.7445.939 · DOI
  75. Ellis, 2004, Australian and New Zealand clinical practice guidelines for the treatment of depression, Australian and New Zealand Journal of Psychiatry, 38, 389, 10.1080/j.1440-1614.2004.01377.x · DOI · Paper page
  76. Feiger, 2003, Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies, International Clinical Psychopharmacology, 18, 203, 10.1097/01.yic.0000073879.27745.23 · doi:10.1097/01.yic.0000073879.27745.23
  77. Feinstein, 2006, In a national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease, Cardiol Rev, 14, 164, 10.1097/01.crd.0000200977.41695.43 · DOI
  78. Friedman, 2007, Expanding the Black Box -- Depression, Antidepressants, and the Risk of Suicide, N Engl J Med, 356, 2343, 10.1056/NEJMp078015 · DOI · Paper page
  79. Furukawa, 2002, Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses, International Journal of Epidemiology, 31, 72, 10.1093/ije/31.1.72 · DOI · Paper page
  80. Furukawa, 2002, Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review, BMJ, 325, 991, 10.1136/bmj.325.7371.991 · DOI
  81. Geddes, 2000, Selective serotonin reuptake inhibitors (SSRIs) for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001851.pub2 · DOI
  82. Geddes, 2004, Depressive disorders, Clinical Evidence, 12, 1391
  83. Goldman, 1999, Awareness, diagnosis and treatment of depression, Journal of General Internal Medicine, 14, 569, 10.1046/j.1525-1497.1999.03478.x · DOI · Paper page
  84. Guy, 1970, Manual for the ECDEU Assessment Battery.2
  85. Heym, 1988, Pharmacology of sertraline: a review, Journal of Clinical Psychiatry, 49 Suppl 8, 40
  86. Imperadore, 2007, Citalopram versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006534 · DOI
  87. Khan, 2003, Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports, Neuropsychopharmacology, 28, 552, 10.1038/sj.npp.1300059 · DOI · Paper page
  88. Koe, 1983, Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin, Journal of Pharmacology and Experimental Therapeutics, 226, 686, 10.1016/S0022-3565(25)21773-6 · DOI · Paper page
  89. Kupfer, 2002, Placebo in clinical trials for depression: complexity and necessity, JAMA, 287, 1853, 10.1001/jama.287.14.1853 · DOI
  90. Lawrenson, 2000, The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared, Journal of Affective Disorders, 59, 149, 10.1016/S0165-0327(99)00147-0 · DOI
  91. Lespérance, 2007, Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial, JAMA, 297, 367, 10.1001/jama.297.4.367 · DOI · Paper page
  92. Linde, 2008, St John's wort for major depression, Cochrane Database of Systematic Reviews
  93. Lu, 2006, Assessing evidence consistency in mixed treatment comparisons, Journal of The American Statistical Association, 101, 447, 10.1198/016214505000001302 · DOI · Paper page
  94. Luborsky, 1962, Clinician's judgments of mental health, Archives of General Psychiatry, 7, 407, 10.1001/archpsyc.1962.01720060019002 · DOI · Paper page
  95. MacQueen, 2001, The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders, CNS Drug Review, 7, 1, 10.1111/j.1527-3458.2001.tb00188.x · DOI
  96. Montgomery, 2004, An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia., Controlled Clinical Trials, 25, 598, 10.1016/j.cct.2004.09.002 · DOI
  97. Nakagawa, 2007, Milnacipran versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006529 · DOI
  98. National Institute for Clinical Excellence, 2004, Depression: management of depression in primary and secondary care
  99. Nose, 2007, Duloxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006533 · DOI
  100. O'Connor, 2005, Pharmacoeconomic analyses of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction, J Clin Psychiatry, 66, 346, 10.4088/JCP.v66n0311 · DOI
  101. Omori, 2006, Fluvoxamine versus other anti-depressive agents for depression. (Protocol), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006114 · DOI
  102. Parker, 2003, Clinical trials of antidepressant medications are producing meaningless results, Br J Psychiatry, 183, 102, 10.1192/bjp.183.2.102 · DOI
  103. Procyshyn, 2004, Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine., Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie, 49, 601, 10.1177/070674370404900905 · DOI
  104. Quitkin, 1991, Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design, Archives of General Psychiatry, 48, 319, 10.1001/archpsyc.1991.01810280035005 · DOI
  105. Smith, 2002, Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis, British Journal of Psychiatry, 180, 396, 10.1192/bjp.180.5.396 · DOI · Paper page
  106. Thase, 1990, Relapse and recurrence in unipolar major depression: short-term and long-term approaches, J Clin Psychiatry, 51, 51
  107. Ware, 1993, SF-36 Health Survey Manual and Interpretation Guide
  108. Watanabe, 2007, Mirtazapine versus other anti-depressive agents for depression (Protocol), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006528 · DOI
  109. World Health Organization, 1978, The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9)
  110. World Health Organization, 1982, The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)
  111. World Health Organisation, 2001, World Health Report 2001: Mental Health: New Understanding, New Hope
  112. Williams, 2000, A systematic review of newer pharmacotherapies for depression in adults: evidence report summary: clinical guidelines, Part 2, Annals of Internal Medicine, 132, 743, 10.7326/0003-4819-132-9-200005020-00011 · DOI · Paper page
  113. Wing, 1994, Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice. London:
  114. Whittington, 2004, Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data, Lancet, 363, 1341, 10.1016/S0140-6736(04)16043-1 · DOI · Paper page
  115. Zwarenstein, 2006, Why are so few randomized trials useful, and what can we do about it?, Journal of Clinical Epidemiology, 59, 1125, 10.1016/j.jclinepi.2006.05.010 · DOI

Cited by

See all 299

Metadata

Authors
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-04-14
Issue
12
Pages
CD006117-CD006117
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd006117.pub4
OpenAlex
W1904816587
Cited by
299
References
32
FWCI
18.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sertraline versus other antidepressive agents for depression. https://app.cochat.ai/papers/10.1002/14651858.cd006117.pub4
The paper
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010). Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006117.pub4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.